Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEO-24 vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline, a xanthine derivative, acts as a non-selective phosphodiesterase (PDE) inhibitor (primarily PDE3 and PDE4), increasing intracellular c AMP and c GMP in airway smooth muscle and inflammatory cells. It also antagonizes adenosine receptors (A1, A2), stimulates endogenous catecholamine release, and may enhance histone deacetylase activity, reducing inflammation.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of symptoms of chronic asthma (FDA-approved),Treatment of chronic obstructive pulmonary disease (COPD) (FDA-approved),Off-label: Apnea of prematurity (though caffeine is preferred),Off-label: Post-extubation stridor in neonates
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
300-600 mg orally once daily, extended-release capsule; individualize based on serum theophylline concentration targeting 5-15 mcg/m L.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal elimination half-life is approximately 3–8 hours in adults (non-smokers), 4–5 hours in smokers (due to enzyme induction), and highly variable in neonates (24–36 hours) and children (1–9 hours). Half-life is prolonged in cirrhosis (up to 30 hours), heart failure, and with concomitant medications (e.g., cimetidine, erythromycin).
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily hepatic via cytochrome P450 CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolized to 1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid. Saturable metabolism leads to non-linear pharmacokinetics at high doses.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Approximately 90% of theophylline is eliminated hepatically via metabolism (principally CYP1A2 and CYP3A4), with less than 10% excreted unchanged in urine. Renal excretion of unchanged drug is minimal (about 5%) in adults. Biliary/fecal excretion accounts for less than 1%.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Approximately 53–65% bound to albumin in plasma. Binding is saturable and decreases at high concentrations, leading to increased free fraction.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
Volume of distribution (Vd) is approximately 0.3–0.7 L/kg (average 0.45 L/kg), indicating distribution into total body water. Vd is larger in neonates and smaller in obese individuals. It does not correlate with therapeutic effect; therapeutic range is based on serum concentration.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral bioavailability is nearly 100% for theophylline base (rapid absorption). For THEO-24 sustained-release capsules, bioavailability is 100% relative to immediate-release, though absorption is slower and p H-dependent. Food may slightly decrease rate but not extent of absorption.
Oral: 40-50%; Inhalation: 20-30%
No specific GFR-based dose adjustment recommended; monitor serum theophylline levels and adjust dose accordingly due to potential accumulation in renal impairment.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
For Child-Pugh class A: reduce dose by 50%; Child-Pugh class B: reduce dose by 50% and monitor levels; Child-Pugh class C: avoid use or use extreme caution with 25% of normal dose and frequent monitoring.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Initial dose: 10-14 mg/kg/day orally in divided doses every 12 hours (extended-release); maximum 300 mg/day for children <1 year; adjust based on serum theophylline levels.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Start at lower end of dosing range (300 mg once daily) with cautious titration; monitor serum theophylline levels closely due to decreased clearance and increased risk of toxicity.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
None
No FDA black box warning.
Narrow therapeutic index; serum concentrations should be monitored (therapeutic range 10-20 mcg/m L for asthma/COPD).,Toxicity risk increased with doses > 400 mg/day or serum levels > 20 mcg/m L; symptoms include nausea, vomiting, diarrhea, headache, insomnia, irritability, and at higher levels, tachycardia, seizures, and cardiac arrest.,Risk of status epilepticus and fatal outcome with seizures.,Use caution in patients with peptic ulcer disease, hyperthyroidism, seizure disorders, hepatic or renal impairment, or cardiac disease (e.g., arrhythmias, congestive heart failure).,Interactions with drugs that inhibit CYP1A2 (e.g., cimetidine, ciprofloxacin, fluvoxamine, macrolides) increase toxicity.,Interactions with drugs that induce CYP1A2 (e.g., rifampin, phenobarbital, carbamazepine, smoking) decrease efficacy.,Elderly, acutely ill, or patients with cor pulmonale have reduced clearance.,Hypersensitivity to theophylline or other xanthines.,Pregnancy category C (risks not ruled out).
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to theophylline or any component of the formulation.,Seizure disorders (relative contraindication; may lower seizure threshold).,Active peptic ulcer disease (relative).,Uncontrolled cardiac arrhythmias (relative).
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
High-protein, low-carbohydrate diets may decrease theophylline clearance. Consumption of charcoal-grilled meats may increase elimination rate. Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may add to stimulant effects and increase toxicity risk.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Theophylline (THEO-24) is pregnancy category C. First trimester: Limited data suggest no increased risk of major malformations; however, rare associations with cardiac defects reported. Second and third trimesters: Possible fetal tachycardia, irritability, and jitteriness at birth due to placental transfer; no known teratogenicity.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Theophylline is excreted into breast milk; M/P ratio approximately 0.7. Infant serum levels can reach therapeutic or toxic ranges. Potential for irritability and insomnia in breastfed infants. Use with caution; monitor infant for signs of theophylline toxicity.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
In pregnancy, theophylline clearance may decrease in the third trimester due to reduced hepatic metabolism. Dose adjustments may be required; monitor serum levels every 2-4 weeks. Postpartum, clearance returns to prepregnancy levels, necessitating dose reduction if dose was increased.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Monitor serum theophylline concentrations; target 5-15 mcg/m L for efficacy and safety. Titrate dose based on steady-state levels. Avoid in seizure disorders unless on anticonvulsants. Cigarette smoking and charbroiled meats increase clearance, requiring dose adjustments. Reduce dose in hepatic impairment, heart failure, and with drugs that inhibit CYP1A2 (e.g., ciprofloxacin, fluvoxamine).
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take exactly as prescribed; do not double doses if missed.,Avoid caffeine-containing products (coffee, tea, chocolate, cola) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew the extended-release capsules; swallow whole.,Inform all healthcare providers you are taking this medication.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEO-24 vs AEROLATE III, answered by our medical review team.
THEO-24 is a Bronchodilator that works by Theophylline, a xanthine derivative, acts as a non-selective phosphodiesterase (PDE) inhibitor (primarily PDE3 and PDE4), increasing intracellular c AMP and c GMP in airway smooth muscle and inflammatory cells. It also antagonizes adenosine receptors (A1, A2), stimulates endogenous catecholamine release, and may enhance histone deacetylase activity, reducing inflammation.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEO-24 and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEO-24 is: 300-600 mg orally once daily, extended-release capsule; individualize based on serum theophylline concentration targeting 5-15 mcg/m L.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEO-24 and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEO-24 is classified as Category C. Theophylline (THEO-24) is pregnancy category C. First trimester: Limited data suggest no increased risk of major malformations; however, rare associations with cardiac defects repo. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.